Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia
NCT ID: NCT01746667
Last Updated: 2017-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2012-02-29
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality Exposure Therapy in Agoraphobic Participants
NCT00734370
Virtual Reality Exposure for Socially Anxious Adolescents
NCT06379633
Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia
NCT06514495
Virtual Reality Exposure Versus In Vivo Exposure for Fear of Heights
NCT04737915
Virtual Reality for Youth Phobias
NCT05839431
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure in vivo
This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing \& Emmelkamp (1993).
Exposure in vivo
Virtual Reality Exposure Therapy
This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.
The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition.
Virtual Reality Exposure Therapy
Wait-list
Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure in vivo
Virtual Reality Exposure Therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* a primary diagnosis of social anxiety disorder as measured with the SCID
* fluency in Dutch.
Exclusion Criteria
* behavior therapy in the preceding one year.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VU University of Amsterdam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul M.G.Emmelkamp
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul GM Emmelkamp, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Amsterdam
Nexhmedin Morina, PhD
Role: STUDY_DIRECTOR
University of Amsterdam
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Amsterdam, Department of Clinical Psychology
Amsterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kampmann IL, Emmelkamp PMG, Morina N. Cognitive predictors of treatment outcome for exposure therapy: do changes in self-efficacy, self-focused attention, and estimated social costs predict symptom improvement in social anxiety disorder? BMC Psychiatry. 2019 Feb 22;19(1):80. doi: 10.1186/s12888-019-2054-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05510207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.